Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

Intravitreal Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO

Inclusion Criteria:

• Patients 18 years of age or older with visual impairment resulting from macular edema secondary to CRVO.
• A BCVA approximate Snellen equivalents, 20/40.

Exclusion Criteria:

• Use of intra-vitreal anti-VEGF injections 3 months or less before baseline.
• Pan-retinal laser photocoagulation 3 months or less before baseline,
• Topical ocular or systemic corticosteroids administered for 30 consecutive days.
• Intraocular or periocular corticosteroid use 3 months or less before screening (study eye),
• Use of intraocular corticosteroid implants,
• Uncontrolled glaucoma (intraocular pressure [IOP] 30 mmHg with medication) at the time of screening or baseline,
• iris neovascularization or neo-vascular glaucoma.